ScreenerHero

MANE Veradermics, Incorporated

NYSE · US · Healthcare · Biotechnology · veradermics.com
110.95USD+1.83%Mkt Cap: 4.64B $P/E: —

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.64B USD
Enterprise Value3.73B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-70.00M USD
Revenue/Share—
Last Price110.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-40.55
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B5.60
EPS (TTM)-4.24
EPS (Forward)-2.69
52W Range
32.0080% of range131.24
52W High131.24 USD
52W Low32.00 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE57.84%
ROA-45.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-71.60M USD
CapEx (TTM)24.00K USD
FCF Margin—
FCF Yield—
Net Debt-819.47M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.00
Current Ratio70.53
Quick Ratio70.25
Book Value/Sh19.47 USD
Cash/Share19.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)163.50 USD
Upside (mean)+47.4%
Target Range135.00 USD – 182.00 USD
135.00+47.4% to mean182.00
# Analysts6
Ownership
Shares Out.41.78M
Float32.29M
Insiders2.49%
Institutions98.38%
Short Interest
Short Ratio7.1d
Short % Float15.09%
Short % Out.9.83%
Shares Short4.11M
Short (prev mo.)4.01M
Technical
SMA 50107.58 (+3.1%)
SMA 20090.04 (+23.2%)
Beta—
S&P 52W Chg15.78%
Avg Vol (30d)677.64K
Avg Vol (10d)768.29K
Technical Indicators
RSI (14)49.9
MACD2.5862
MACD Signal2.9105
MACD Hist.-0.3243
BB Upper125.67 USD
BB Middle111.32 USD
BB Lower96.97 USD
BB Width25.78%
ATR (14)6.123 USD
Vol Ratio (20d)0.87x